Current opinion of immunotherapy for ocular allergy

Current Opinion in Allergy and Clinical Immunology

Volumn 2, Issue 5, 2002, Pages 447-452

  Bielory, Leonard ^a   Mongia, Anu ^a  

^a INSTITUTE OF OPHTHALMOLOGY AND VISUAL SCIENCE   (United States)

Author keywords

Allergic conjunctivitis; Immunotherapy

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; DNA VACCINE; GRASS POLLEN EXTRACT; HOUSE DUST ALLERGEN; PARIETARIA EXTRACT; PLASMID DNA; POLLEN EXTRACT; RAGWEED ANTIGEN; UNCLASSIFIED DRUG;

ALLERGIC CONJUNCTIVITIS; ATOPY; BIRCH POLLEN; BRONCHUS HYPERREACTIVITY; CLINICAL TRIAL; CPG ISLAND; DIFFERENTIAL DIAGNOSIS; DNA SEQUENCE; DRUG EFFICACY; GENE THERAPY; HEALTH CARE COST; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; NONHUMAN; OLIVE POLLEN; PRIORITY JOURNAL; PROVOCATION TEST; REVIEW; RHINOCONJUNCTIVITIS; TH1 CELL; TREATMENT INDICATION; VACCINATION;

EID: 0036773127     PISSN: 15284050     EISSN: None     Source Type: Journal    
DOI: 10.1097/00130832-200210000-00013     Document Type: Review

References (79)

1. Lowell FC, Franklin W. A double-blind study of the effectiveness and specificity of injection therapy in ragweed hay fever. N Engl J Med 1965; 73:675-679
2. Juniper EF, Kline PA, Ramsdale EH, Hargreave FE. Comparison of the efficacy and side effects of aqueous steroid nasal spray (budesonide) and allergen-injection therapy (Pollinex-R) in the treatment of seasonal allergic rhinoconjuctivitis. J Allergy Clin Immunol 1990; 85:606-611.
3. Del Prete A, Loffredo C, Caqrderopoli A, et al. Local specific immunotherapy in allergic conjunctivitis. Acta Ophthalmol (Copenh) 1994; 72:631-634.
4. Gaglani B, Borish L, Bartelson BL, et al. Nasal immunotherapy in weed-induced allergic rhinitis. Ann Allergy Asthma Immunol 1997; 79:259-265.
5. Balda BR, Wolf H, Baumgarten C, et al. Tree-pollen allergy is efficiently treated by short-term (STI) with seven preseasonal injections of molecular standardized allergens. Allergy 1998; 53:740-748.
6. Dreborg S, Agrell B, Foucard T, et al. A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I: Clinical results. Allergy 1986; 41:131-140.
7. Horak F, Stubner P, Berger UE, et al. Immunotherapy with sublingual birch pollen extract: A short-term double-blind placebo study. J Investig Allergol Clin Immunol 1998; 8:165-171.
8. Noon L, Cantab B. Prophylactic inoculation against hay fever. Lancet 1911; 1:1572-1573.
9. McAllister CG, Wiggert B, Chader GJ, et al. Uveitogenic potential of lymphocytes sensitized to interphotoreceptor retinoid-binding protein. J Immunol 1987; 138:1416-1420.
10. Rocha G, Baines MG, Deschenes J. The immunology of the eye and its systemic interactions. Crit Rev Immunol 1992; 12:81-100.
11. Dick AD, Cheng YF, Liversidge J, Forrester JV. Immunomodulation of experimental autoimmune uveoretinitis: A model of tolerance induction with retinal antigens. Eye 1994; 8 (Pt 1):52-59.
12. Lailotou B, Liversidge J, Forrester JV, Dick AD. Interphotoreceptor retinoid binding protein is a potent tolerogen in Lewis rat: Suppression of experimental autoimmune uveoretinitis is retinal antigen specific. Br J Ophthalmol 1997; 81:61-67.
13. Nussenblatt RB. Basic and clinical immunology in uveitis. Jpn J Ophthalmol 1987; 31:368-374.
14. Mizuno K, Altman NF, Clark AF, Streilein JW. Histopathologic analysis of experimental autoimmune uveitis attenuated by intracameral injection of S-antigen. Curr Eye Res 1989; 8:113-121.
15. Ni M, Chan CC, Mao W, Nussenblatt RB. Immunopharmacological studies of qingkaining, a Chinese blended medicine: Effects on experimental autoimmune uveoretinitis in the rat. Immunol Invest 1989; 18:907-917.
16. Mochizuki M. Immunotherapy in ocular diseases. Nippon Ganka Gakkai Zasshi 1992; 96:1608-1634.
17. Vrabec TR, Gregerson DS, Dua HS, Donoso LA. Inhibition of experimental autoimmune uveoretinitis by oral administration of S-antigen and synthetic peptides. Autoimmunity 1992; 12:175-184.
18. Gormley PD, Powell-Richards AO, Azuara-Blano A, et al. Lymphocyte subsets in conjuctival mucosa-associated-lymphoid-tissue after exposure to retinal. S-antigen. Int Opthalmol 1998-99; 22:77-80.
19. Hirose S, Wiggert B, Redmond TM, et al. Uveitis induced in primates by IRBP: Humoral and cellular immune responses. Exp Eye Res 1987; 45:695-702.
20. Hara Y, Caspi RR, Wiggert B, et al. Suppression of experimental autoimmune uveitis in mice by injection of anterior chamber-associated immune deviation with interphotoreceptor retinoid-binding protein. J Immunol 1992; 148:1685-1692.
21. Ohta K, Wiggert B, Taylor AW, Streilein JW. Effects of experimental ocular inflammation on ocular immune privilege. Invest Ophthalmol Vis Sci 1999; 40:2010-2018.
22. Olsen OT, Froulund L, Heinig J, et al. A double blind, randomized study investigating the efficacy and specificity of immunotherapy with Artemisia vulgaris or Phleum pratense/betula verrucosa. Allergol Immunopathol (Madr) 1995; 23:73-78.
23. Winther L, Malling HJ, Moseholm L, Mosbech H. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. Allergy 2000; 55:818-826.
24. Koizumi T, Abe T. Induction of oral tolerance to experimental allergic conjunctivitis in rats. Nippon Ganka Gakkai Zasshi 1995; 99:515-520.
25. Machida H, Nakagami T, Watanabe I. Local ocular immunotherapy for experimental allergic conjunctivitis. Jpn J Ophthalmol 2000; 44:634-638. This study is important because it shows beneficial effects of immunotherapy when used topically for allergic conjunctivitis and serves as an excellent model for treatment modalities for allergic conjunctivitis.
26. Miyazaki D, Liu G, Clark L, Ono SJ. Prevention of acute allergic conjunctivitis and late-phase inflammation with immunostimulatory DNA sequences. Invest Ophthalmol Vis Sci 2000; 41:3850-3855.
27. Taudorf E, Laursen LC, Lanner A, et al. Oral immunotherapy in birch pollen hay fever. J Allergy Clin Immunol 1987; 80:153-161.
28. Hordijk GJ, Antvelink JB, Luwema RA. Sublingual immunotherapy with a standardized grass pollen extract, a double-blind placebo-controlled study. Allergol Immunopathol (Madr) 1998; 26:234-240.
29. Pradalier A, Basset D, Claudel A, et al. Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. Allergy 1999; 54:819-828.
30. Friedlaender MH. Conjunctivitis of allergic origin: Clinical presentation and differential diagnosis. Surv Ophthalmol 1993; 38:S105-S114.
31. Nathan RA, Meltzer EO, Selner JC, Storms W. Prevalence of allergic rhinitis in the United States. J Allergy Clin Immunol 1997; 99:S808-S814.
32. Hjern A, Haglund B, Hedlin G. Ethnicity, childhood environment and atopic disorder. Clin Exp Allergy 2000; 30:521-528.
33. Ray NF, Baraniuk JN, Thamer M, et al. Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses. J Allergy Clin Immunol 1999; 103 (3 Pt 1):401-407.
34. Bielory L. Allergic and immunologic disorders of the eye. II: Ocular allergy. J Allergy Clin Immunol 2000; 106:1019-1032.
35. Liu G, Keane-Myers A, Miyazaki D, et al. Molecular and cellular aspects of allergic conjunctivitis. Chem Immunol 1999; 73:39-58.
36. Bielory L. Therapeutic targets in the allergic eye disease. Allergy Asthma Proc 2001; 22:25-28.
37. Buckley RJ. Allergic eye disease: A clinical challenge. Clin Exp Allergy 1998; 28 (Suppl 6):39-43.
38. Magone TM, Chi-Chao C, Rizzo LV, et al. A novel murine model of allergic conjunctivitis. Clin Immunol Immunopath 1998; 87:75-84.
39. Allansmith MR, Baird RS, Ross RN, et al. Ocular anaphylaxis induced in the rat by topical application of compound 48/80: Dose response and time course study. Acta Ophthalmol Suppl 1989; 192:145-153.
40. Merayo-Lloves J, Calonge M, Foster CS. Experimental model of allergic conjunctivitis to ragweed in guinea pig. Curr Eye Res 1995; 14:487-494.
41. Stenback H, Krootila D, Palkama A, Uusitalo H. Mast cells in the anterior uvea of the rabbit: Intraocular effects of compound 48/80 in the rabbit. Exp Eye Res 1992; 54:247-252.
42. Magone MT, Chan CC, Beck L, et al. Systemic or mucosal administration of immunostimulatory DNA inhibits early and late phases of murine allergic conjunctivitis. Eur J Immunol 2000; 30:1841-1850. This study uses up to date technology of immunostimulatory DNA to influence allergic conjunctivitis.
43. Spiegelberg HL, Orozco EM, Roman M, Raz E. DNA immunization: A novel approach to allergen-specific immunotherapy. Allergy 1997; 52:964-970.
44. Beck L, Spiegelberg HL. The polyclonal and antigen-specific IgE and IgG subclass response of mice injected with ovalbumin in alum or complete Freund's adjuvant. Cell Immunol 1989; 123:1-8.
45. Varney VA, Gaga M, Frew AJ, et al. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991; 302:265-269.
46. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass pollen immunotherapy. N Engl J Med 1999; 341:468-475. This supports the long term efficacy of immunotherapy.
47. Linna O, Kokkonen J, Lukin M. A 10-year prognosis for childhood allergic rhinitis. Acta Paediatr 1992; 81:100-102.
48. Rackemann FM, Edwards RN. Asthma in children: A follow-up study of 688 patients after an interval of twenty years. N Engl J Med 1952; 246:815-823.
49. Pedersen PA, Weeke ER. Asthma and allergic rhinitis in the same patients. Allergy 1983; 38:25-29.
50. Adkinson NF Jr. Immunotherapy for allergic rhinitis. N Engl J Med 1999; 341:522-524.
51. La Rosa M, Ranno C, Andre C, et al. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999; 104 (2 Pt 1):425-432.
52. Ortolani C, Pastorello EA, Incorvaia C, et al. A double-blind, placebo-controlled study of immunotherapy with an alginate-conjugated extract of Parietaria judaica in patients with Parietaria hay fever. Allergy 1994; 49:13-21.
53. Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109:251-256. This study shows that employing IT early can alter the natural progression of atopic diseases.
54. Horst M, Hejjaoui A, Horst V, et al. Double-blind, placebo-controlled rusch immunotherapy with standardized Alternaria extract. J Allergy Clin Immunol 1990; 85:460-472.
55. Walker SM, Pajno GB, Lima MT, et al. Grass pollen immunotherapy for seasonal rhinitis and asthma: A randomized, controlled trial. J Allergy Clin Immunol 2001; 107:87-93.
56. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991; 21:77-83.
57. Madonini E, Briatico-Vangosa G, Pappacoda A, et al. Seasonal increase of bronchial reactivity in allergic rhinitis. J Allergy Clin Immunol 1987; 79:358-363.
58. Walker SM, Varney VA, Gaga M, et al. Grass pollen immunotherapy: Efficacy and safety during a 4-year follow-up study. Allergy 1995; 50:405-413.
59. Pocobelli D, Del Bono A, Venuti L, et al. Nasal immunotherapy at constant dosage: A double-blinded, placebo-controlled study in grass-allergic conjunctivitis. J Investig Allergol Clin Immunol 2001; 11:79-88.
60. Alvarez-Cuesta E, Cuesta-Herranz J, Puyana-Ruiz J, et al. Monoclonal antibody-standardized cat extract immunotherapy: Risk-benefit effects from a double-blind placebo study. Allergy Clin Immunol 1994; 93:556-566.
61. Prakash OM, Murthy KR. Immunotherapy in allergic conjunctivitis. Indian J Ophthalmol 1992; 40:9-10.
62. Andre C, Vatrinet C, Galvain S, et al. Safety of sublingual-swallow immunotherapy in children and adults. Int Arch Allergy Immunol 2000; 121:229-234.
63. Pacor ML, Biasi D, Carletto A, et al. Oral immunotherapy in oculorhinitis from Gramineae. Recenti Prog Med 1996; 87:4-6.
64. Feliziani V, Lattuda G, Parmiani S, Dall'Aglio PP. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts: A double blind study. Allergol Immunopathol (Madr) 1995; 23:224-230.
65. Sabbah A, Hassoun S, Le Sellin J, et al. A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy 1994; 49:309-313.
66. Bousquet J, Maasch HJ, Hajjaoui A, et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. III: Efficacy and safety of unfractionated and high-molecular-weight preparations in rhinoconjunctivitis and asthma. J Allergy Clin Immunol 1989; 84 (4 Pt 1):546-556.
67. Purello-D'Ambrosio F, Gangemi S, Isola S, et al. Sublingual immunotherapy: A double-blind, placebo controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both. Allergy 1999; 54:968-973.
68. Moller C, Biorksten B, Nilsson G, Dreborg S. The precision of the conjunctival provocation test. Allergy 1984; 39:37-41.
69. Passalacqua G, Albano M, Riccio A, et al. Clinical and immunologic effects of rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial. J Allergy Clin Immunol 1999; 104:964-968.
70. Di Rienzo V, Puccinelli P, Frati F, Parmiani S. Grass pollen specific sublingual/swallow immunotherapy in children: Open-controlled comparison among different treatment protocols. Allergol Immunopathol (Madr) 1999; 27:145-151.
71. Vourdas D, Syrigou E, Potamianou P, et al. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 1998; 53:662-672.
72. Passalacqua G, Albano M, Gregonese L, et al. Randomized controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998; 351:629-632.
73. Lofkvist T, Agrell B, Dreborg S, Svensson G. Effects of immunotherapy with purified standardized allergen preparation of dermatophagoides farinae in adults with perennial allergic rhinoconjunctivitis. Allergy 1994; 49:100-107.
74. Nunez JA, Cuesta U. Local conjunctival immunotherapy: The effect of dermatophagoides pteronyssinus local conjunctival immunotherapy on conjunctival provocation test in patients with allergic: Conjunctivitis. Allergol Immunopathol 2000; 28:301-306.
75. Moller C, Dreborg S, Lanner A, Bjorksten B. Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy: A double blind study. Allergy 1986; 41:271-279.
76. Donovan JP, Buckeridge DL, Briscoe MP, et al. Efficacy of immunotherapy to ragweed antigen tested by controlled antigen exposure. Ann Allergy Asthma Immunol 1996; 77:74-80.
77. Winther L, Malling HJ, Mosbech H. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. Allergy 2000; 55:827-835.
78. Adkinson NF Jr. Con: Immunotherapy is not clinically indicated in the management of allergic asthma. Am J Respir Crit Care Med 2001; 164:2140-2141; discussion 2141-2142.
79. Bousquet J. Pro: Immunotherapy is clinically indicated in the management of allergic asthma. Am J Respir Crit Care Med 2001; 164:2139-2140; discussion 2141-2142.